Determinants of disease and disability in the elderly: The Rotterdam elderly study

Hofman, Albert; Grobbee, Diederick E.; Jong, Paulus T. V. M. de; Ouweland, F. A. Van Den

doi:10.1007/bf00145007

Cited by 1,015 publications

(734 citation statements)

References 93 publications

Supporting

Mentioning

727

Contrasting

Unclassified

Order By: Relevance

“…Insulin resistance as calculated by the HOMA insulin resistance index (HOMA IR) was also not significantly different between the different genotypes (p >0.3, Table 1). Trends observed in the initial cohort could not be replicated in an independent population-based sample from the Rotterdam study (Type 2 DM, n=95 and NGT, n=188, data not shown) [5]. A priori power calculations showed that we had an 80 percent power to detect differences in allele frequency around 10 percent.…”

mentioning

confidence: 87%

Lack of association between gene variants in the ALMS1 gene and Type 2 diabetes mellitus

Hart

Dekker²,

Heine³

et al. 2003

Diabetologia

View full text Add to dashboard Cite

mentioning

confidence: 87%

Lack of association between gene variants in the ALMS1 gene and Type 2 diabetes mellitus

Hart

Dekker²,

Heine³

et al. 2003

Diabetologia

View full text Add to dashboard Cite

“…The Rotterdam Study is a prospective populationbased cohort study of neurological, cardiovascular, locomotor and ophthalmological diseases in the elderly [16]. In brief, all inhabitants of Ommoord aged 55 years or older who were living in this municipal area of Rotterdam were invited in 1990-1993 to participate in the study.…”

Section: Settingmentioning

confidence: 99%

Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study

Beiderbeck-Noll

Sturkenboom

Linden

et al. 2003

European Journal of Cancer

View full text Add to dashboard Cite

The association between the use of calcium channel blockers (CCB) and cancer has received ample attention, but is still controversial. In this study, we have tested the hypothesis that the observed association between CCB and cancer in earlier studies could be explained by residual confounding or by misclassification of exposure because of the use of cross-sectional data on drug use. Data from the Rotterdam Study, a prospective population-based cohort study in the municipal area Ommoord, were used. The study population consisted of a cohort of 3204 participants aged 71 years or older who were followed from a baseline interview in the period 1991-1993 for the occurrence of incident cancer. Data on drug use were gathered at baseline and through the seven community pharmacies which served the Ommoord region during the study period between 1 January 1991 and 1 January 1999. Incident cancer events were gathered from a nationwide registry of hospitalisation data and from a specialised cancer centre in the Rotterdam region. We performed three analyses. First, we followed the method, and adjusted for the same risk factors, as in the earlier studies. In the second analysis, we included all risk factors that were univariately associated with cancer in the Rotterdam Study. In the third analysis, we included exposure to CCBs as time-varying co-variates, while adjusting for potential confounders. The relative risk (RR) of cancer associated with CCB was 1.4 (95% Confidence Interval (CI): 0.9-2.0) in the first analysis and lowered to 1.2 (95% CI: 0.8-1.8) upon adjustment for the different co-variates in the second. In both analyses, however, verapamil was significantly associated with cancer with RRs of 2.1 (95% CI: 1.1-4.0) and 2.0 (1.01-3.9), respectively, whereas no associations were found with the other CCB in this study, i.e. diltiazem and nifedipine. A significantly increased risk of cancer was found for intermediate daily doses of verapamil and diltiazem. Intake of other antihypertensives such as b-blocking agents, diuretics and ACE-inhibitors was not associated with cancer. In the third analysis with exposure to CCB as time-varying co-variates, the risk increase was non-significant for use of 2 years or less, 1.0 (95% CI: 0.7-1.5), and for use for a cumulative period of more than 2 years, 1.3 (95% CI: 0.8-2.0). However, in all models the hazard ratio was statistically significantly increased for verapamil, but not for diltiazem and nifedipine. On the basis of these analyses, we found no increase in cancer in users of diltiazem and nifedipine, nor in users of other antihypertensives. In line with earlier studies, however, we found an increased risk of cancer in users of verapamil. At variance with the conclusions from several other studies, we think that it is too early to conclude that CCB are not associated with cancer. #

show abstract

“…Its general aims are to investigate determinants of chronic diseases. 26 During the first phase of this study (1990)(1991)(1992)(1993), all inhabitants of a Rotterdam suburban area (Ommoord) aged 55 years and over were invited to participate in this study. The response rate was 78%.…”

Section: Methodsmentioning

confidence: 99%

“…A more in depth description of the Rotterdam Study was published previously. 26 Genotyping Genomic DNA was extracted from samples of peripheral venous blood according to standard procedures. Genomic DNA 1-2 ng was dispensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, CA, USA).…”

Section: Methodsmentioning

confidence: 99%

TGF-β1 polymorphisms and arterial stiffness; the Rotterdam Study

et al. 2007

View full text Add to dashboard Cite

Arterial stiffness is a risk factor for cardiovascular disease. Transforming growth factor b1 is a pleiotropic cytokine, with many functions, including influence on the vascular wall (e.g., on angiogenesis, endothelial cells and the extracellular matrix). We investigated five functional polymorphisms in the transforming growth factor b1 gene (À800 G/A, À509 C/T, codon 10 Leu/Pro, codon 25 Arg/Pro and codon 263 Thr/Ile) in relation to arterial stiffness in a population-based study. A total of 3863 participants of the Rotterdam Study, a prospective population-based study, were included in the current study. The relations of the genotypes and haplotypes with arterial stiffness (pulse wave velocity (PWV), distensibility coefficient (DC) and pulse pressure (PP)) were studied using analyses of variance and linear regression. The analyses were adjusted for age, sex, mean arterial pressure, heart rate, conventional cardiovascular risk factors and measures of atherosclerosis. There were no associations between PWV and À800 G/A (P ¼ 0.56), À509 C/T (P ¼ 0.29), codon 10 (P ¼ 0.98) and, codon 25 (P ¼ 0.28). These polymorphisms were not associated with the DC or with PP. The haplotype-based analyses yielded similar results. The results of this study show that the TGF-b1 -800 G/A, À509 C/T, codon 10 Leu/Pro and codon 25 Arg/Pro polymorphisms are not associated with arterial stiffness.

show abstract

Determinants of disease and disability in the elderly: The Rotterdam elderly study

Cited by 1,015 publications

References 93 publications

Lack of association between gene variants in the ALMS1 gene and Type 2 diabetes mellitus

Lack of association between gene variants in the ALMS1 gene and Type 2 diabetes mellitus

Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study

TGF-β1 polymorphisms and arterial stiffness; the Rotterdam Study

Contact Info

Product

Resources

About